↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Rascol A, Maurel H, David J, Layani M (1974). „[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]” (French). Thérapie29 (1): 95–9. PMID4603757.
Hache J, Duchene-Marullaz P, Streichenberger G (1974). „[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]” (French). Thérapie29 (1): 81–93. PMID4849381.
Constantin M, Pognat JF (1979). „Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites”. Arzneimittel-Forschung29 (1): 109–14. PMID582104.
Bertolino A, palermo M, Porro V (1985). „Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes.”. Acta Ther (11): 209–218.
Aguglia E (1986). „On the therapetic value of axaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations.”. Acta Ther (12): 259–267.